{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:26:28Z","timestamp":1790519188595,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1136\/ard.2010.142000","type":"journal-article","created":{"date-parts":[[2011,3,7]],"date-time":"2011-03-07T01:13:11Z","timestamp":1299460391000},"page":"1104-1107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis"],"prefix":"10.1016","volume":"70","author":[{"given":"Elizabeth N","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick M","family":"Wigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami A","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K","family":"Hummers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2010.142000_bib1","first-page":"581","article-title":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","author":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.142000_bib2","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.142000_bib3","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/art.24681","article-title":"Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.","volume":"60","author":"Amjadi","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.142000_bib4","first-page":"1271","article-title":"Variability of skin scores and clinical measurements in scleroderma.","volume":"22","author":"Pope","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.142000_bib5","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.","volume":"22","author":"Clements","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.142000_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.1790040106","article-title":"The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis.","volume":"4","author":"Poole","year":"1991","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard.2010.142000_bib7","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing.","volume":"26","author":"Medsger","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.142000_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population.","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/ard.2010.142000_bib9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1164\/arrd.1987.135.4.805","article-title":"The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit.","volume":"135","author":"Knudson","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1136\/ard.2010.142000_bib10","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","article-title":"A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.","volume":"48","author":"Derk","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.142000_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/rheumatology\/40.1.84","article-title":"Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma.","volume":"40","author":"Stratton","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.142000_bib12","first-page":"287","article-title":"A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.","volume":"25","author":"Vanthuyne","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2010.142000_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3899\/jrheum.090668","article-title":"Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.","volume":"37","author":"Herrick","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.142000_bib14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2013a retrospective analysis.","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.142000_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","article-title":"Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.","volume":"102","author":"Zamora","year":"2008","journal-title":"Respir Med"},{"key":"10.1136\/ard.2010.142000_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.","volume":"133","author":"Gerbino","year":"2008","journal-title":"Chest"},{"key":"10.1136\/ard.2010.142000_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"key":"10.1136\/ard.2010.142000_bib18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","article-title":"Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.","volume":"45","author":"Liossis","year":"2006","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724101161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724101161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2010.142000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T09:21:27Z","timestamp":1736068887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724101161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0003496724101161"],"URL":"https:\/\/doi.org\/10.1136\/ard.2010.142000","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2010.142000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}